Welcome to our dedicated page for NSPX news (Ticker: NSPX), a resource for investors and traders seeking the latest updates and insights on NSPX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NSPX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NSPX's position in the market.
Inspyr Therapeutics has implemented a new corporate strategy focused on precision therapeutics for cancer treatment, acquiring a proprietary portfolio of adenosine immuno-modulator compounds. The lead asset, RT-AR001, is on track for pre-IND filing in H1 2021. The firm has strengthened its pipeline and increased its cash runway to mid-2022, securing $1.25 million from an existing investor. Financially, Inspyr reported a net loss of $6.36 million for 2020, with cash and restricted cash rising to $404,000 from $23,000 in 2019.
Inspyr Therapeutics, Inc. (OTC PINK:NSPX) has expanded its global intellectual property portfolio by securing additional patents for adenosine receptor antagonists in China, Eurasia, and Israel. This expansion enhances the company's flexibility in developing targeted cancer treatments. With 18 patents already issued in various markets, including the U.S. and Europe, the company is advancing its investigational new drug (IND) applications and pre-clinical research. The rising cancer incidence in these regions emphasizes the significance of their novel therapies.
Inspyr Therapeutics (OTC PINK:NSPX) has expanded its patent portfolio with 18 new patents focused on novel adenosine receptor antagonists. This strategic move enhances the company's ability to develop targeted precision therapeutics for cancer treatments across various global markets, including the US and Europe. The expansion supports the research of RT-AR001, a potential first-in-class therapeutic. The company is also advancing its corporate strategy, initiating pre-clinical research, manufacturing, and regulatory efforts to create value for stakeholders.
Inspyr Therapeutics (OTC PINK:NSPX) reported its Q3 2020 financial results, showcasing a strategic shift towards precision therapeutics for cancer treatment. The company secured $500,000 from existing investors and strengthened its collaboration with Ridgeway Therapeutics by reacquiring a novel immune-oncology platform. The cash position decreased to $33,000 while the operating loss remained stable at $137,000. Notably, Inspyr reported a net income of $2,106,000 due to gains in the change of derivative liability and debt conversion, compared to a net loss in the previous year.
Inspyr Therapeutics, Inc. (OTC/PINK:NSPX) announced the acquisition of a novel immuno-oncology delivery technology that targets adenosine receptor antagonists for cancer treatment. The company reacquired this technology from Ridgeway Therapeutics, receiving rights to all related proprietary assets and improvements. The deal involved issuing 65 million shares of Common Stock and 8,000 shares of Series F Convertible Preferred Stock. The technology is expected to enhance drug delivery within tumors, potentially improving treatment outcomes.
